Journal
CLINICAL & EXPERIMENTAL METASTASIS
Volume 26, Issue 2, Pages 153-159Publisher
SPRINGER
DOI: 10.1007/s10585-008-9225-8
Keywords
Breast cancer; Metastasis; Biomarker; Mena; Splice variant
Categories
Funding
- Anna Fuller Molecular Oncology Fund
- Ludwig Center for Molecular Oncology
- NIH [CA 100324, CA113395, GM58801, 1-U54-CA112967]
- Lega Italiana per la Lotta Contro i Tumori
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- Breast Cancer Alliance Inc
Ask authors/readers for more resources
We have studied the gene expression pattern of invasive primary mammary tumor cells using a unique in vivo invasion assay that isolates the invasive tumor cells by chemotaxis. One of the genes upregulated in the invasive tumor cells is Mena, an actin binding protein involved in the regulation of cell motility. There are multiple known splice variants of Mena accounted for by four alternatively included exons, +, ++, +++ and 11a. Using the in vivo invasion assay in rats and mice with mammary tumors we observed that two isoforms of Mena, ++ and +++, are upregulated in the invasive tumor cells and one isoform, 11a, is downregulated. The Mena isoform switching pattern described here may provide a new biomarker for the presence of metastatic cancer cells and for prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available